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Abstract
Background: Erlotinib is a Human Epidermal Growth Factor Receptor Type 1/tyrosine kinase
(EGFR) inhibitor which is used for non-small-cell lung cancer treatment. Despite that erlotinib is
considered to have a favorable safety profile, adverse events such as interstitial lung disease (ILD)
were reported in pivotal studies. The authors report the first histologically confirmed case of fatal
ILD associated with erlotinib therapy.
Case Presentation: The medical record of a patient who developed fatal ILD after receiving
erlotinib treatment was reviewed to identify the cause of death and other factors potentially
contributive to this adverse outcome. A 55-year-old smoker with no evidence of pre-existing
interstitial disease developed bilateral ILD and respiratory failure which could be explained only as
a toxicity of erlotinib. He had a history of stage IV left upper lobe squamous-cell carcinoma for
which he had received three successive regimens of chemotherapy (ifosfamide plus gemcitabine,
docetaxel, mitomycin plus navelbine), followed five months later by erlotinib. At initiation of
erlotinib treatment there were no radiological signs suggestive of ILD disease or apparent clinical
signs of respiratory distress. While the patient completed two months with erlotinib therapy he
developed bilateral interstitial infiltrates; despite discontinuation of erlotinib he was admitted with
respiratory failure two weeks later. Diagnostic work up for other causes of pneumonitis including
infectious diseases, congestive cardiac failure and pulmonary infraction was negative. Empiric
treatment with oxygene, corticosteroids and later with cyclophosphamide was ineffective and the
patient progressively deteriorated and died. The clinical and post-mortem examination findings are
presented and the possible association relationship between erlotinib induced ILD and previous
chemotherapy is discussed.
Conclusion: Physicians should be alert to the fact that erlotinib related ILD, although infrequent,
is potential fatal. The association between selective EGFR-inhibitors and ILD should be further
investigated.
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Erlotinib (Tarceva®) is an Epidermal Growth Factor Recep-
tor Type 1/tyrosine kinase (HER1/EGFR) inhibitor. The
development of erlotinib in the treatment of advanced
non-small-cell-lung cancer (NSCLC) raised a great enthu-
siasm among physicians. The initial safety and efficacy
clinical studies showed some prolonged remissions and,
in some cases, dramatic improvement in the quality of life
in patients whose condition was no longer responding to
standard chemotherapy. However, adverse events associ-
ated with erlotinib treatment, such as diarrhoea and rush,
less often conjunctivitis and keratitis and rarely interstitial
lung disease (ILD) have been observed [1]. We report the
first histologically confirmed case of fatal ILD associated
with erlotinib therapy.
Case presentation
In January 2006, a 55-year-old smoker was admitted in
our hospital with acute respiratory failure. The patient
reported one-week of progressive exertional dyspnoea but
denying chest pain, haemoptysis, increased cough or
fever. He had a history of chronic obstructive pulmonary
disease [baseline values: FEV1 = 900 ml (or 35 %pre-
dicted), FVC = 2.1 L (or 56 %predicted), FEV1/FVC(%pre-
dicted) = 45] while stage IV left upper lobe squamous-cell
carcinoma was diagnosed fourteen months ago. He had
received three successive regimens of chemotherapy (ifos-
famide plus gemcitabine, between August and December
2004, docetaxel, between January 2005 and April 2005
and mitomycin plus vinorelbine tartrate, between April
and May 2005), followed by erlotinib on October 2005.
Two months later, while on erlotinib, he was restaged for
his cancer. At that time clinical examination revealed min-
imal non productive cough and the presence of a facial
exantheme which is a common side effect of erlotinib; the
Karnofski index was 90% and oxygen saturation at rest
was 96%. Computed Tomography showed no response of
the primary tumour but revealed newly appearing bilat-
eral diffuse ground-glass opacities (Figure 1); there was no
evidence of pulmonary infraction/emboli. Because of
reports of erlotinib associated ILD[1] the drug was with-
drawn. However, two weeks later the patient was admitted
with severe dyspnea. His temperature was 36.6°C, his
blood pressure was 120/60 mmHg, pulse was 120 beats
per minute. He was tachypnoeic with 30 breaths per
minute. Arterial blood gasses at rest (FiO2 = 0.21) were:
PaO2 43 mmHg and PaCO2 53 mmHg. Cardiovascular
evaluation was normal with no evidence of significant
jugular venous distension or peripheral oedema. Chest
examination revealed bibasilar inspiratory crackles. Leu-
cocyte cell count was 12/mm3 with 67% neutrophils. All
cultures and stains for infectious etiologies including
common bacteria, fungi, pneumocystis, legionella, nocar-
dia, viruses were negative. Sputum and gastric fluid cul-
ture proved negative for mycobacteria three weeks later.
The patient was started on supplemental oxygen and iv.
methylprednisolone (1 mg/Kg daily and then 3 g bolus
therapy after one week) and empiric therapy was
expanded one week later to include cyclophosphamide
(500 mg). Despite transient clinical improvement, hypox-
emia persisted and oxygen requirements increased. The
patient progressively deteriorated and died three weeks
later.
At autopsy, the heart was normal with no signs of globoid
enlargement of atrials or ventricles, nor signs of cardiac
ischemia. The lungs appeared enlarged. Macroscopic
examination revealed a 6.5 cm upper left mass and a 1.5
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was proved to be a squamous cell carcinoma. Both lungs
showed homogenous airspace consolidation predominat-
ing at the lower lobe of the right lung. Microscopic exam-
ination showed scattered lesions of organizing
pneumonia and thickening of the vascular walls mainly in
the peritumoral parenchyma, probably related to the
effects of chemotherapy. At low magnification (Figure 2),
alveolar spaces were enlarged and surrounded by patchy
interstitial fibrosis distributed throughout the lungs, and
lined by hyperplastic type II pneumocytes, suggestive of
the organizing stage of a diffuse alveolar damage. Some
thrombi were observed in small-sized pulmonary arteri-
oles. At autopsy, there was no evidence of infection, carci-
nomatous lymphangitis or cardiogenic pulmonary
oedema.
Discussion
The present case demonstrated that erlotinib may be asso-
ciated with fatal ILD. Erlotinib either caused or contrib-
uted significantly to the pulmonary damage, and thus this
drug must be considered among the antineoplastic agents
which can cause or contribute to interstitial pulmonary
disease. This is important information since erlotinib is
considered as a new promising oral chemotherapy agent
in NSCLC, with a favourable safety profile[1]. To our
knowledge, this is the first histologically confirmed case
of fatal ILD, associated with erlotinib treatment.
Tammaro et al[2] reported a case of ILD following erlo-
tinib diagnosed on basis of clinical and radiological crite-
ria, without histological confirmation. In that case, a
favourable outcome was observed with steroids. Marked
improvement in symptoms and radiologic signs was
noted when the patient had completed one month ther-
apy with prednisolone. However, severe pulmonary
adverse events, including fatalities had been reported with
another EGFR-inhibitor (gefinitib-Iressa®)[3]. Thus, FDA
advises that erlotinib should be suspended pending eval-
uation, on the appearance of new pulmonary symptoms
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present case confirms that the outcome of erlotinib
related ILD may be extremely unfavourable[1]. The onset
of the disease was indolent and, once patent, progressed
until death despite withdrawn of erlotinib and adminis-
tration of empiric treatment.
The diagnosis of drug-induced ILD relies on typical radio-
logic features and exclusion of other potential causes. In
our case radiologic signs of ILD were apparent within the
first two months of erlotinib treatment in accordance with
the report of previous studies [1-3]. The diagnosis of erlo-
tinib induced pulmonary injury was made by excluding
other potential causes such as congestive heart failure,
infections, or lymphangitic carcinomatosis. Thoracic radi-
ation or pre-existing interstitial disease that have been
reported to contribute to ILD secondary to EGFR-inhibi-
tors[3] were not present in our case. It should be under-
lined here that patients on erlotinib have usually already
received treatment with various antineoplastic agents. Pre-
vious chemotherapy was reported as a predisposing factor
for gefinitib related ILD[3]. Interstitial pneumonitis, acute
hypersensitivity pneumonitis, acute permeability edema
with or without acute respiratory distress syndrome were
described for gemcitabine[4], mitomycin[5], vinorelbine
tartrate[6], docetaxel[7], or ifosfamide[8] and occur usu-
ally early after the administration of chemotherapy.
Whether erlotinib can induce pulmonary toxicity by a
mechanism related to its unique properties or contributes
significantly to pulmonary toxicity induced by prior
chemotherapy, it remains to be investigated.
The incidence of ILD was less than 1% in erlotinib pivotal
trials[1]. However, the incidence could be higher since
ILD diagnosis requires diagnostic work up that may not be
always feasible in patients with advanced non-small-lung
cancer and/or co-morbidities. Notably, the frequency of
ILD associated to gefinitib appeared to be higher in case
series[3] and observational studies[9] than in pivotal tri-
als[10]. Thus, clinical studies would be helpful to confirm
whether the incidence of erlotinib related ILD is as low as
0.6% especially considering the potential danger immi-
nent in erlotinib related ILD.
Conclusion
In conclusion, physicians should be alert to the fact that
ILD following erlotinib, although infrequent, is poten-
tially fatal. This observation reinforces FDA advice regard-
ing the necessary alertness of physicians to detect early
radiographic signs of ILD in patients on erlotinib. The
association between selective EGFR-inhibitors and ILD
should be further investigated.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
DM drafted the manuscript and participated in data col-
lection. AS participated in the design and coordination of
the case-study and revised the article for important intel-
lectual content. MCC carried out the histological exami-
nation. GC participated in the preparation of the
manuscript and in the data collection. LB carried out
autopsy and participated in the histological examination.
JJL participated in the preparation of this article by revis-
ing it for important intellectual content. CHM coordi-
nated the study and revised the article for important
intellectual content. All authors read and approved the
final manuscript.
Acknowledgements
Written consent was obtained from patient's relative for publication of 
study.
References
1. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R: FDA drug
approval summary: erlotinib (Tarceva) tablets.  The Oncologist
2005, 10:461-466.
2. Tammaro KA, Baldwin PD, Lundberg AS: Interstitial lung disease
following erlotinib (Tarceva) in a patient who previously tol-
erated gefitinib (Iressa).  J Oncol Pharm Pract 2005, 11:127-130.
3. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina
M, Kikuchi T, Moriya T, Nukiwa T: Severe acute interstitial pneu-
monia and gefitinib.  Lancet 2003, 361:137-139.
4. Pavlakis N, Bell DR, Millward MJ, Levi JA: Fatal pulmonary toxicity
resulting from treatment with gemcitabine.  Cancer 1997,
80:286-291.
5. Orwoll ES, Kiessling PJ, Patterson JR: Interstitial pneumonia from
mitomycin.  Ann Intern Med 1978, 89:352-355.
6. Kouroukis C, Hings I: Respiratory failure following vinorelbine
tartrate infusion in a patient with non-small cell lung cancer.
Chest 1997, 112:846-848.
7. Read WL, Mortimer JE, Picus J: Severe Interstitial Pneumonitis
Associated with Docetaxel Administration.  Cancer 2002,
94:847-853.
8. Baker WJ, Fistel SJ, Jones RV, Weiss RB: Interstitial pneumonitis
associated with ifosfamide therapy.  Cancer 1990, 65:2217-2221.
9. Shih YN, Chiu CH, Tsai CM, Perng RP: Interstitial pneumonia
during gefitinib treatment of non-small-cell lung cancer.  J
Chin Med Assoc 2005, 68:183-186.
10. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard
JY, Nishiwaki Y, Vansteenkiste J, Kudh S, Rischin D, Eek R, Horai T,
Noda K, Taketa I, Smit E, Averdush S, Macleod A, Feyereislova A,
Dong RP, Baselga J: Multi-Institutional randomized phase II
trial of gefitinib for previously treated patients with
advanced non-small-cell lung cancer.  J Clin Oncol 2003,
21:2237-2246.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/7/150/pre
pubPage 4 of 4
(page number not for citation purposes)
